CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 480 enrolled
Drug / intervention
XIENCE V EECSS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01923740
NCT01923740N/ACompleted
CompareCT.gov

A Clinical Evaluation of Absorb™ BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population

Abbott Medical Devices·interventional·Posted Aug 16, 2013·Updated Dec 4, 2019

In Brief

A clinical study evaluating XIENCE V EECSS and Absorb BVS System for Coronary Artery Disease and 3 related conditions. Completed, enrolled 480 participants across 1 site.

Detailed Summary

To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 16, 2013
Enrollment StartJul 1, 2013
Primary CompletionMay 1, 2015
Study CompletionMar 7, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.9 years ago

Interventions

XIENCE V EECSSdevice

Subjects receiving XIENCE V

Absorb BVS Systemdevice

Subjects receiving Absorb BVS System